Atropos Health, the pioneer of a smart clinical analytics platform designed to transform clinical data into high-quality, real-world evidence for healthcare, has secured a $33 million Series B funding to scale its performance.
The new funding announced on Thursday, May 23, 2024, came shortly after healthcare institutions, research institutions, data platforms, and life sciences companies adopted its generative AI platform, GENEVA OS™, signaling the growing confidence in company’s offerings.
Atropos Health’s funding round was Led by Valtruis, with significant contributions from new investors, including McKesson Ventures, Cencora Ventures, Merck Global Health Innovation Fund, and existing investors Breyer Capital, Presidio Ventures, and Emerson Collective.
Founded in 2019, Atropos Health was originally developed as the “Green Button” project at Stanford University by leaders in the application of Artificial Intelligence (AI) and evidence research in healthcare Brigham Hyde Ph.D., Saurabh Gombar M.D., Ph.D., and Nigam Shah MBBS, Ph.D.
Since then, the company has grown to become a leader in applying generative AI in healthcare technology systems. One notable application is ChatRWD™, which reduces the time required to create high-quality publication-grade real-world evidence from months to a few minutes.
ChatRWD™ was designed to facilitate access to high-quality, real-world evidence to improve healthcare decision-making processes and outcomes. With new investments secured, Atropos plans to use the funding to strengthen its standing in value-based care.
